PRECIGEN, INC. Impairment of Intangible Assets, Finite-lived
PRECIGEN, INC. (PGEN) reported Impairment of Intangible Assets, Finite-lived of $32.32 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2024-11-14
- PRECIGEN, INC. impairment of intangible assets, finite-lived for the quarter ending 2024-06-30 was $32.32M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 3 month as first filed |
|---|---|---|
| 2024-06-30 | $32.32M 10-Q · filed 2024-11-14 | -$32.32M 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |